Genomic Valley Biotech Complete Financial Statements
In FYNone, Genomic Valley Biotech (GVBL) reported revenue ₹1 Cr, net profit ₹0 Cr and EPS ₹-0.20. Full financial statements from FY2015 to FY2025 (11 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. For live price, earnings ratios and company overview, see GVBL share price.
Complete Financial Data Export
Profitability Ratios
Balance Sheet Ratios
GVBL Revenue, Net Profit & EBITDA — Year-on-Year Growth
GVBL YoY (March 2025 vs Period). Review GVBL P/E ratio to evaluate earnings-based valuation against sector peers.
GVBL Income Statement — Revenue, EBITDA & Net Profit
Genomic Valley Biotech revenue ₹1 Cr, EBITDA ₹0 Cr, net profit ₹0 Cr, EPS ₹-0.20 (None). Explore GVBL intrinsic value to estimate fundamental worth using multiple valuation models.
| Particulars | None | March 2025 | March 2024 | March 2023 | March 2022 | March 2021 | March 2020 | March 2019 | March 2018 | March 2017 | March 2016 | March 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1 | 1 | 0 | 3 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 0 |
| Expenses | 1 | 0 | 0 | 2 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 0 |
| EBITDA | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Operating Profit Margin % | 13.00% | 52.00% | 9.00% | 32.00% | -535.00% | -66.00% | 65.00% | 42.00% | 17.00% | -23.00% | -422.00% | -249.00% |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 0 | 0 | 0 | 1 | 0 | -1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Profit | 0 | 0 | 0 | 1 | 0 | -1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Earnings Per Share (₹) | -0.20 | 1.17 | 0.05 | 2.12 | -0.03 | -1.83 | 0.94 | 0.76 | 0.11 | -0.22 | -1.10 | -0.03 |
GVBL Balance Sheet — Assets, Liabilities & Shareholders' Equity
GVBL total assets ₹4 Cr, total equity ₹4 Cr, total liabilities ₹ Cr (2025).
| Particulars | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||||
| Total Assets | 4 | 4 | 4 | 4 | 8 | 8 | 7 | 7 | 6 | 6 | 6 |
| Current Assets | 3 | 3 | 3 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Fixed Assets | 0 | 0 | 0 | 2 | 6 | 5 | 4 | 4 | 4 | 3 | 3 |
| Capital Work in Progress | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 4 | 4 | 4 | 2 | 1 | 3 | 2 | 2 | 2 | 3 | 3 |
| LIABILITIES | |||||||||||
| Total Liabilities | |||||||||||
| Current Liabilities | 0 | 0 | 0 | 1 | 2 | 2 | 2 | 1 | 1 | 1 | 1 |
| Non-Current Liabilities | |||||||||||
| SHAREHOLDERS' EQUITY | |||||||||||
| Total Equity | 4 | 4 | 4 | 3 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Share Capital | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Reserves & Surplus | 1 | 1 | 1 | 0 | 1 | 2 | 2 | 2 | 1 | 2 | 2 |
GVBL Cash Flow Statement — Operating, Investing & Financing
Genomic Valley Biotech operating cash flow ₹0 Cr, investing ₹0 Cr, financing ₹0 Cr, net cash flow ₹0 Cr (2025).
| Particulars | March 2025 | March 2024 | March 2023 | March 2022 | March 2021 | March 2020 | March 2019 | March 2018 | March 2017 | March 2016 | March 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 0 | 0 | -1 | -2 | 2 | 0 | -1 | 1 | 0 | -1 | 0 |
| Investing Activities | 0 | 0 | 2 | 4 | -2 | -1 | 0 | -1 | 0 | 1 | -1 |
| Financing Activities | 0 | 0 | -1 | -2 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Net Cash Flow | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1 |